Last updated: February 15, 2026
What is the Drug with NDC 00998-0615?
NDC 00998-0615 is the drug Lomitapide marketed under the brand name Juxtapid. It is approved by the FDA for treating familial hypercholesterolemia, a genetic disorder characterized by high cholesterol levels that increase the risk of cardiovascular disease.
What Are the Current Market Dynamics?
Market Size and Patient Population
- Estimated annual prevalence of homozygous familial hypercholesterolemia (HoFH): approximately 1,300-1,500 patients in the U.S.
- Estimated untreated mortality risk: high, with progressive cardiovascular disease
- Treatment adoption remains limited due to high cost and safety concerns
Commercial Adoption
- Significant uptake in specialty clinics
- Around 300-400 patients estimated to be on therapy in the U.S. (as of 2022)
- Key competitor: Mipomersen (a competing antisense oligonucleotide), with limited market share due to safety profiles
Distribution Channels
- Specialty pharmacies dominate distribution
- Insurance coverage impacts patient access; high copays and prior authorizations restrict uptake
Regulatory Status
- FDA approved in 2012
- European approval granted in 2016
- Recent efforts to expand indications and improve safety profile are ongoing
How Is the Market Expected to Evolve?
Drivers
- Growing awareness of familial hypercholesterolemia
- Advances in genetic diagnosis
- Development of combination therapies
Barriers
- High treatment costs (~$450,000 annually)
- Strict safety monitoring requirements
- Limited patient population
Potential Market Expansion
- New indications, such as liver-related cholesterol disorders
- Expanded labeling in pediatric populations
- Potential entry of biosimilars or generics (not currently available)
What Are the Price Projections?
Current Pricing
- Wholesale acquisition cost (WAC): approximately $410,000 - $450,000 per year per patient (Varies with dosing and insurance negotiations)
- Average net price after discounts: estimated at $350,000 - $400,000
Short-term Outlook (Next 2-3 Years)
- Market growth driven by increased diagnosis and treatment initiation
- Anticipated incremental revenue increase of 10-15% annually, reaching $140 million to $200 million globally by 2025
Long-term Projections (3-5 Years)
- Potential price reduction due to insurance negotiations and market saturation
- Introduction of biosimilars or alternative therapies could exert downward pressure
- Market value could decline to $100 million - $150 million if new treatments emerge or if price controls tighten
Competitive Landscape and Its Impact on Pricing
- Current competition limited; brand dominance persists
- Main competitor Mipomersen has withdrawn from many markets due to lack of approval and safety concerns
- Biosimilars unlikely within 3-5 years, but potential if patents expire in 2028 or later
Policy and Payer Trends Affecting Pricing
- Increasing emphasis on value-based pricing models
- Prior authorization trends restrict access
- Potential for NHS and other global health bodies to negotiate lower prices
Summarized Price Projections Table
| Year |
Estimated Global Revenue |
Expected Price Range per Patient |
Key Factors Influencing Price |
| 2023 |
$140M - $150M |
$350,000 - $400,000 |
Market expansion, insurance negotiations |
| 2024 |
$155M - $180M |
Stable but potential slight decline |
Market penetration increasing, policy tightening |
| 2025 |
$170M - $200M |
Slight decrease to $340,000 |
Entry of biosimilars expected in late 2020s |
Key Takeaways
- The drug's market remains niche with limited patient access due to cost and safety concerns.
- Short-term revenue growth is moderate; long-term pricing could decline due to biosimilar competition.
- The primary growth driver is increased diagnosis and treatment of familial hypercholesterolemia.
- Pricing remains high relative to other specialty lipid-lowering agents.
- Market dynamics will be heavily influenced by policy, insurance practices, and potential new therapies.
FAQs
1. How does the price of lomitapide compare to other lipid-lowering therapies?
Lomitapide's annual cost (~$350,000–$450,000) exceeds most general lipid-lowering drugs like statins, which cost a few hundred dollars a year, highlighting its niche status for severe monogenic hypercholesterolemia.
2. Is lomitapide set to lose market share soon?
Potentially, if biosimilars or new therapies with better safety profiles enter the market. Currently, market share is constrained by high costs and safety concerns rather than a lack of efficacy.
3. What policies could influence future pricing?
Price negotiations through managed care, value-based agreements, and global drug price controls could lower costs, especially in public healthcare systems.
4. What is the scope for expanding lomitapide’s indications?
Research into additional lipid disorders and pediatric populations could enlarge the patient base, possibly affecting price strategies.
5. Are there safety concerns affecting market penetration?
Yes. Liver toxicity and gastrointestinal side effects restrict broader use, requiring ongoing safety monitoring impacting treatment adoption and reimbursement.
Sources:
[1] FDA Drug Database.
[2] IQVIA Sales Data.
[3] Company Financial and Marketing Reports.
[4] European Medicines Agency.
[5] Pricing and reimbursement analyses by global health agencies.
